• Bausch + Lomb has launched its EyeGility Inserter in the U.S., a preloaded intraocular lens delivery system tailored for its enVista Aspire IOLs and, soon, enVista Envy lenses, aiming to offer smoother, one-handed cataract lens implantation through a 2.4mm incision.
• This new inserter emphasizes surgeon convenience and reliability, with features like balanced push force and extended standby time that could make Bausch + Lomb’s premium IOL platforms more appealing in everyday cataract practice.
• Next, we’ll examine how EyeGility’s focus on smoother, one-handed premium IOL delivery could influence Bausch + Lomb’s broader investment narrative.

The latest GPUs need a type of rare earth metal called Terbium and there are only 29 companies in the world exploring or producing it. Find the list for free.

Bausch + Lomb Investment Narrative Recap

To own Bausch + Lomb, you need to believe in its ability to turn a broad eye care portfolio into sustainable profitability while improving margins. The EyeGility Inserter fits into that story by trying to strengthen premium cataract offerings, but on its own it does not change the central near term catalyst, which is execution on higher margin Pharma and Vision Care growth, nor the main risk that the company remains loss making despite rising sales.

The most relevant recent announcement here is the European rollout of preloaded enVista Envy IOLs, which already referenced EyeGility as part of the platform. Together, European Envy uptake and the U.S. EyeGility launch highlight how much of the thesis now leans on premium IOL recovery after the enVista recall and whether this product family can support the mix shift that consensus expects for gross margin improvement.

Yet investors should also weigh how dependent this premium IOL recovery story is on regaining surgeon trust after the enVista recall and whether...

Bausch + Lomb's narrative projects $6.2 billion revenue and $265.5 million earnings by 2029. This requires 5.9% yearly revenue growth and a $484.5 million earnings increase from -$219.0 million today.

Uncover how Bausch + Lomb's forecasts yield a $17.88 fair value, a 11% upside to its current price.

Exploring Other Perspectives

Compared with the consensus story, the most bearish analysts paint a stricter bar, assuming only 5.5% annual revenue growth to about US$6.1 billion and 2029 earnings of roughly US$238 million. In that pessimistic view, execution risks around premium IOL recovery and programs like EyeGility loom larger, which is exactly why it can be useful for you to compare these assumptions with your own and consider how this new launch might shift the range of outcomes.

Explore 5 other fair value estimates on Bausch + Lomb - why the stock might be worth just $17.88!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Bausch + Lomb research is our analysis highlighting 3 key rewards that could impact your investment decision.
• Our free Bausch + Lomb research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Bausch + Lomb's overall financial health at a glance.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• Capitalize on the AI infrastructure supercycle with our selection of the 55 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.